Oral Solid Dosage Contract Manufacturing Market

Category : Healthcare & Life Sciences Reports | Delivery Format : PDF,PPT | Publisher: Reports and Insights | Pages : 248

To learn more about this report, request a free sample copy

Oral Solid Dosage Contract Manufacturing Market Overview

The report is titled as ‘Oral Solid Dosage Contract Manufacturing Market: Opportunity Analysis and Future Assessment 2022-2030’. An overview of conceptual frameworks, analytical approaches of the Oral Solid Dosage Contract Manufacturing market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market.

The oral solid dosage contract manufacturing market is estimated to reach at a value of US$ 33.0 Bn by the end of 2022 and expected to reach at a value of US$ 49.7 Bn by 2030 with a significant CAGR of 5.3%.

Oral Solid Dosage Contract Manufacturing Introduction

The oral solid dosage refers to the term that alludes to a conclusive drug product therapy that is consumed through the mouth, dispersed in the digestive tract, and dispensed to the body via absorption into the blood flow. Some of the few examples of oral solid dosage (OSD) forms include tablets, small molecules, soft gels, capsules, gummies, effervescence, and pills. Oral solid dosage (OSD) products can be developed in various different shapes, and with those various forms comes up different production approaches and facility blueprints. Oral solid dosage has gained immense population in the present times and thus it has turned out a dominant delivery form all across the global market for majorly three grounds.

Firstly, it is comparatively simple to administer, it is simple to differentiate one oral solid dosage product from another, and lastly, the oral solid dosage manufacturing techniques are well-developed and well understood. There are contract research organizations, across the world, which are mainly outsourced companies that offer support to biotechnology and pharmaceutical companies in their clinical and preclinical analyses on the basis of an agreement.

In addition, the oral solid dosage form contract manufacturers either put forward new and innovative products or upgrade older products. The rising incidences of chronic diseases as well as soaring demand for effective treatments and therapeutics is primarily driving the growth of the global oral solid dosage contract manufacturing market over the forthcoming years.

Oral Solid Dosage Contract Manufacturing Market Segmentation

The global oral solid dosage contract manufacturing market is segmented on the basis of type, formulation, therapeutic area, dosage form, molecule type, and region.

By Type

Early Phase Development Services

Chemistry, Manufacturing & Control

Preclinical Services

Discovery Studies

Clinical Research Services

Phase I

Phase II

Phase III

Phase IV

Laboratory Services

Bioanalytical Testing

Analytical Testing

Physical Characterization

Raw Material Testing

Batch Release Testing

Stability Testing

Other Analytical Testing

Consulting Services

Data Management Services

By Formulation

Delayed Release

Immediate Release

Sustained Release

Orally Disintegrating Tablets

By Therapeutic Area

Oncology

Infectious Diseases

Neurology

CVS

Metabolic Disorders/Endocrinology

Other Therapeutic Areas

By Dosage Form

Tablets

Conventional Release

Modified Release

Chewable Tablets

Effervescent Tablets

Capsules

Hard Gelatin Capsules

Soft Gelatin

Capsules/Softgels

Powders & Granules

Lozenges & Pastilles

Gummies

By Molecule Type

Small molecule API manufacturers

Biologics API Manufacturing

By Region

North America

Latin America

Europe

Asia Pacific

Middle East

Africa

Oral Solid Dosage Contract Manufacturing Market Key Players

Some of the key participating players in global oral solid dosage contract manufacturing market are:

Recipharm

Aenova Holding

Catalent

AbbVie

Patheon N.V. (Thermo Fisher Scientific)

NextPharma

Capsugel (Lonza Group AG)

Aurobindo Pharma Limited

Siegfried AG

Piramal Pharma Solutions

Corden Pharma

Kremoint Pharma Pvt Ltd.

HERMES PHARMA GmbH

Medipaams India Private Limited

Alpex Pharma

Abaris Healthcare Pvt Ltd

Ardena Holdings N.V

Aphena Pharma Solutions

Actiza Pharmaceutical Private Limited

Sunwin Healthcare PVT. LTD

Saffron Medicare PVT. LTD

Kosher Pharmaceuticals

Dr Reddy’s Lab

GlaxoSmithKline Plc

Boehringer Ingelheim

BioXcellence                                               

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

New product designs and launches

Current product compliance

Reimbursement

Concerns for use of Oral Solid Dosage Contract Manufacturing

Advantages of Oral Solid Dosage Contract Manufacturing

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decisions.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s product sales, previous growth rates and market expansion plans are considered to generate market share in the market.


To learn more about this report, request a free sample copy


Select License Type

Frequently Asked Questions

The oral solid dosage contract manufacturing market is estimated to reach at a value of US$ 33.0 Bn by the end of 2022 and expected to reach at a value of US$ 49.7 Bn by 2030 with a significant CAGR of 5.3%.

The base year for the report is 2021 in oral solid dosage contract manufacturing market.

The global oral solid dosage contract manufacturing market is segmented on the basis of type, formulation, therapeutic area, dosage form, molecule type, and region.

Recipharm, Aenova Holding, Catalent, AbbVie, Patheon N.V. (Thermo Fisher Scientific), NextPharma, Capsugel (Lonza Group AG), Aurobindo Pharma Limited, Siegfried AG, Piramal Pharma Solutions, Corden Pharma, Kremoint Pharma Pvt Ltd., HERMES PHARMA GmbH, Medipaams India Private Limited, Alpex Pharma, Abaris Healthcare Pvt Ltd, Ardena Holdings N.V, Aphena Pharma Solutions, Actiza Pharmaceutical Private Limited, Sunwin Healthcare PVT. LTD, Saffron Medicare PVT. LTD,Kosher Pharmaceuticals, Dr Reddy’s Lab, GlaxoSmithKline Plc, and Boehringer Ingelheim, BioXcellence



This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

OK